Kornimate/medical-research-clean huggingface dataset:
effects of high load strength training with and without tissue specific planter facia stretching with planter fasciitis

Conditions: Plantar Fascitis; Resistance Training; Muscle Stretching Exercises

Summary: the rationale behind examining the synergistic impacts of high load strength training and tissues pecific plantar fascia stretching activities in athletes diagnosed with plantar fasciitis arises from an acknowledged deficiency in the existing body of scholarly research.study design will be randomized control trial. the study will be completed in 10 months after synopsis approval.the study will be carried in sports clubs of moth mirpur ajk. convenient sampling will be used. data collection tools will be used named as vas, functional foot index (ffi), and goniometry used for pain, functional disability and range of motion will be measured respectively before and after the intervention

population is divided into 2 groups: group a and group b. both groups will be given a patient evaluation sheet and thickness of planter fascia will be already measured by ultrasound. group a will then receive high load strength training and routine physiotherapy. group b will receive high load strength training and tissue-specific plantar fascia stretching exercise and routine physiotherapy. pain, range of motion and functional disability will be measured before session, immediate effect after first session, then after 06 weeks (18 session) with high load strength training maximum repetition 12 rm with 3 sets in alternative days in each set minimum 2 mint rest interval and tissue specific plantar fascia stretching exercise perform for 10 times for 10 sec, after 12 weeks (36 sessions) with high load strength training maximum repetition 10 rm with 4 sets in alternative days in each set minimum 2 mint rest interval tissue specific plantar fascia stretching exercise perform for 10 times for 10 sedate will be entered and analyzed by spss version 21. statistical significance will be p=0.05 descriptive statistics: frequency tables, pie charts, bar charts will be used.

Eligibility criteria:
inclusion criteria: * only male athletes * prediagnosed patients suffering from plantar fasciitis referred from orthopedic. * history of inferior heel pain atleast 2 weeks before enrollement. * pain on palpation of medial calcaneal tubercle/proximal plantar fascia. * all participants with in the age group between 20-35 yrs. * patients who are willing to particiapate in the study. * heel pain syndrome exclusion criteria: * history of any systemic disease * heel and skin infection * history of prior surgery * corticosteroid injection for plantar fasciitis within previous 06 momths; * any known malignancy /neoplasma involved side. * diagnosed/known psychiatric illness

Keywords: plantar heel pain,high-load strength training,
kawasaki disease during the covid-19 epidemic

Conditions: Kawasaki Disease

Summary: northern italy is the second region hit by the sars-cov2 infection worldwide. data on covid-19 clinical presentation in children is still scarce, but fewer rate of infection and milder disease seem typical of this age group. in the last three weeks it has been reported an abnormal number of critically ill patients with clinical characteristics consistent with kawasaki shock syndrome (kss). the common manifestations are: "middle aged" children (6-9 y/o) with a history of persistent high spiking fever in the last days, abdominal pain, diarrhea, skin rash and rapidly deteriorating clinical condition with the onset of shock, without clear signs of dehydration. other less common features are arthralgia, cough, meningism, conjunctivitis and reddened, cracked lips. labworks usually show high inflammatory markers, low lymphocyte counts, low sodium, and high troponin levels. echocardiography have been consistent with myocarditis in the majority of patient instead of classical coronary artery abnormalities. patients have been diagnosed as kawasaki disease (typical or incomplete) and treated accordingly with intravenous immunoglobulin (ivig) and/or steroids. one patient refractory to such treatments responded successfully to intravenous anakinra. all the patients reported a family history consistent with covid-19, serology and naso-pharyngeal swabs were inconsistently positive. to date we are aware of at least 10 such cases. kss is a rare and dreadful complication, with an estimated prevalence of 5% of patients with kawasaki disease (kd). given the extreme rarity of this condition, the occurrence of so many cases in the last weeks points to a possible causative agent. as our hospitals are in high endemic area, sars-cov2 seems the most obvious, although testing for such infection in patients returned conflicting results. it is not clear, at this moment, if this clinical entity is a proper kd triggered by sars-cov2, or a systemic vasculitis with similar features of kd, secondary to sars-cov2 infection. the aim of this nationwide study is to better define this clinical entity.


Eligibility criteria:
inclusion criteria: * all children with clinical diagnosis of kawasaki disease * age\<18 years * absence of other underlying chronic diseases exclusion criteria: * presence of underlying chronic diseases * not fulfilling clinical criteria for kawasaki disease diagnosis

Keywords: kawasaki disease sars-cov-2 children
reducing hospital falls by empowering nurses to provide ambulatory aids

Conditions: Accidental Falls; Harm Reduction

Summary: this project proposes to evaluate the potential for nurses to assess if a patient who uses an ambulatory aid at home is fit to use one in the hospital, and the effect that providing ambulatory aids to hospitalized patients will have on reducing hospital falls, with a matched pair cluster-randomized controlled trial. hypothesis 1: of the patients who use an ambulatory aid at home, patients who receive an ambulatory aid in the hospital will have a lower fall rate as compared to patients who do not receive an ambulatory aid in the hospital. hypothesis 2: after adequate training, nurses will be able to accurately assess whether or not patients need an ambulatory aid when compared to the gold-standard assessments of physical therapists.

this research project proposes to study the effectiveness of a specific falls prevention intervention in a high risk population by providing ambulatory aids upon admission to the hospital to patients who previously used one at home after a standardized evaluation by a registered nurse. this will be a randomized controlled trial within three hospitals in a large academic medical center. primary objectives: specific aim 1: evaluate the effectiveness in preventing falls by providing an ambulatory aid to patients who use an ambulatory aid at home, and who are deemed fit to use the device in the hospital by their nurse. specific aim 2: evaluate the nurses' ability to assess the appropriateness of providing an ambulatory aid, such as a cane or walker, to a patient who uses an assistive device at home.

Eligibility criteria:
inclusion criteria: * any one determined to be in need of walking aid and * can stand up from a seated position independently without assistance * can use ambulatory aid at home without assistance/supervision * can sit up in bed and rise to a standing position independently exclusion criteria: * not able to give consent * not able to use ambulatory aid independently

Keywords: fall prevention hospital acquired conditions nurse education assistive devices
bioequivalence of single dose fast release aspirin (1000 mg) tablet versus single dose of two 500 mg fast release aspirin tablets

Conditions: Pain

Summary: the primary objective of this study is to compare the bioavailability of a single dose of a new 1000 mg fast release asa (acetylsalicylic acid) tablet with that of two tablets of a commercially available 500 mg fast release tablet and to test for bioequivalence of the new versus the commercial product in healthy adult subjects.


Eligibility criteria:
inclusion criteria: * healthy ambulatory male and female subjects 18 to 55 years of age, inclusive * body mass index (bmi) of approximately 18.5 to 30.0 kg/m2, and a total body weight \>50 kg (110 lbs) * results of screening and clinical laboratory tests are within normal limits or considered not clinically significant by the principal investigator or sponsor * female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, intramuscular injection or double-barrier and have a negative pregnancy test at screening and on day 0 of each treatment period. female subjects of nonchildbearing potential must be amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy. * provide a personally signed and dated informed consent prior to inclusion in the trial indicating that the subject has been informed of all pertinent aspects of the trial. exclusion criteria: * history of hypersensitivity to acetylsalicylic acid (asa), naproxen sodium, acetaminophen, other non-steroidal anti-inflammatory drugs (nsaids), and similar pharmacological agents or components of the products * history of gastrointestinal bleeding or perforation, including bleeding related to previous nsaid therapy. active, or history of recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding). * have taken asa, asa-containing products, acetaminophen or any other nsaid (otc or prescription) seven days prior to dosing or during the treatment periods, other than study product * loss of blood in excess of 500 ml within 56 days of the first dose of trial treatment (e.g., donation, plasmapheresis, or injury) * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic disease, or malignancies * positive alcohol or drug screen at screening or on day 0 of treatment periods 1 or 2 * females who are pregnant or lactating * consumption of xanthine-containing food and beverages within 24 h before investigational medicinal product (imp) administration during treatment periods 1 and 2; or not willing to abstain from any xanthine containing food and beverages during the study
expanded access study of hboc-201 (hemopure) for the treatment of life-threatening anemia

Conditions: Anemia

Summary: the purpose of this expanded access study is to be able to provide treatment with hboc-201 to patients with life-threatening anemia for whom blood is not an option. hboc-201 is not fda approved for use in the united states, but is approved as an oxygen carrier in south africa and russia.

i. initial dose for patients with a hemoglobin level less than 6 mg/dl, an initial dose of 32.5 g (one unit) of hboc 201 is recommended, to be followed by infusion of additional units as necessary to achieve and maintain a total hemoglobin concentration above 6 g/dl, provided that the patient's circulatory volume is properly controlled and will not impose an inappropriate risk. ii. subsequent doses the need for additional dose administration should be assessed after each infusion as clinically indicated. dosing will be stopped if any one of the following occurs: * resolution of critical ischemia * death * recovery of native hemoglobin levels to \> 6 g/dl, * evidence of reticulocytosis

Eligibility criteria:
inclusion criteria: 1. patients \> = 18 years of age 2. patients with hemoglobin \< = 8g/dl with with active bleeding, physiologic evidence of critical ischemia, for example: elevated troponins, altered mental status, acute renal failure, lactic acidosis or central nervous system supply dependency 3. patients or their legally authorized representatives who are able and willing to provide informed consent exclusion criteria: 1. patients with known hypersensitivity or allergy to beef products 2. patients with pre-existing uncontrolled hypertension, heart failure, renal failure, circulatory hypervolemia or systemic mastocytosis (on a case by case and quality of life determination) 3. patients \> 80 years of age (on a case by case and quality of life determination) 4. patients who are eligible for blood transfusions

Keywords: life-threatening anemia blood alternative hboc
efficacy of postural reeducation in elite gymnasts with back pain

Conditions: Back Pain; Back Strain Lower Back; Athletic Injuries

Summary: introduction: low back pain is a musculoskeletal disorder that is associated with symptoms such as pain, limitation of joint range and postural problems in athletes. methods: the study design is a randomized controlled clinical trial with a minimum of 35 elite gymnasts with back pain. two postural treatments will be implemented, mezieres method and isostretching to verify if there is improvement of back pain in gymnasts and to compare both procedures. discussion: this trial could generate a greater understanding of the importance of posture related to low back pain and its possible treatments.

a randomized controlled clinical trial with two groups (intervention and placebo) will be implemented. the intervention group will have the mezieres technique as postural treatment while the placebo group will follow a total of 6 isostretching positions. in total, the two treatments with 30 minutes and duration or with a frequency of 2 weekly sessions will be implemented for a period of 12 weeks. all treatments will be performed by the same certified therapist and with a minimum of 5 years of experience in postural treatments. the measurements will be made immediately after the first session, in 2 weeks, 6 weeks and in the last week of intervention by a blind researcher who did not participate in the treatments, but with experience in this field.

Eligibility criteria:
inclusion criteria: * elite gymnastic athletes with low back pain * active participation in the national competition * practice at least three times a week for 60 minutes * minimum training time of 7 hours a week exclusion criteria: * gymnast whom suffer from chronic disease or acute musculoskeletal injury * herniated disc * spondylolisthesis

Keywords: physiotherapy rehabilitation treatment isostretching postural treatment
trial of an educational intervention to promote spectacle use among secondary school children in islamabad, pakistan

Conditions: Refractive Errors; Visual Impairment

Summary: this study is planned to test an educational intervention promoting the use of spectacles among secondary school children. it is based on the hypothesis that educating teachers, parents and children about the importance of wearing spectacles has the potential to increase spectacle wear among children.reasons for non-compliance towards spectacle use will be explored and educational intervention will be planned considering these reasons. educational intervention will increase awareness about the importance of spectacles use and reduce the barriers towards spectacle use.reducing barriers will increase compliance towards spectacles use which will ultimately prevent the avoidable visual impairment.

aim of this research is to improve school performance and quality of life of children with refractive errors. planned research will be carried out in eight (4 girls and 4 boys) public sector secondary schools of islamabad and vision of students will be tested with standard snellen chart to recruit 120 boys and 120 girls with refractive errors. students having vision ≤ 6/12 will receive auto refraction and prescription of spectacles will be given after subjective refraction. primary outcome of purchase of glasses will be asessed at three months after prescribing. follow up after six months of prescribing spectacles will find out compliance towards spectacles. non-compliant students will be given a questionnaire to provide the reasons for non-compliance towards spectacles. focus group discussions (fgds) will be conducted with non-compliant students, their teachers and parents to explore reasons of non compliance. on the basis of information obtained from fgds an educational intervention will be planned for students, their parents and teahers to explain importance of spectacles. through stratified randomization schools will be assigned to intervention and control groups. four schools including two girls and two boys schools will be assigned to intervention group and four schools (two girls and two boys) will be assigned to control group. educational intervention will be given to intervention group. six months after the intervention compliance to spectacle wear will be assessed than pre and post intervention compliance in intervention group and between two groups will be compared to assess effectiveness of intervention.

Eligibility criteria:
inclusion criteria:- 1- children from 6th to 9th grade (approximate age, 11-16 years) of secondary schools in islamabad. exclusion criteria: 1. children from 10th grade which is the final grade of secondary schools. 2. children with eye disorders other than refractive error.
efficiency of a mechanical device in controlling tracheal cuff pressure in intubated critically ill patients

Conditions: Cuff Overinflation; Cuff Underinflation

Summary: despite intermittent control of tracheal cuff pressure using a manual manometer, cuff underinflation and overinflation frequently occur in critically ill patients, resulting in increased risk for microaspiration and tracheal ischemic lesions.

the aim of this study is to determine the efficiency of pressure easy® device (smiths medical cuff pressure controller) in continuous control of tracheal cuff pressure.

Eligibility criteria:
inclusion criteria: * patients intubated in the icu with a polyvinyl chloride (pvc) cuffed tracheal tube. * predicted duration of mechanical ventilation \> or = 48h. * age \> or = 18 years. * signed informed consent. exclusion criteria: * anticipated duration of mechanical ventilation\<48h after randomization. * tracheostomized patients. * patients with contraindication for semirecumbent position. * patients participating to another trial that might influence this study results.

Keywords: tracheal cuff cuff overinflation cuff underinflation
hand held nitrous oxide delivery device

Conditions: Anesthesia

Summary: to study the safety and efficacy of hand held nitrous. a device that delivers 120 seconds of up to 72% nitrous oxide and ambient air.

this study assesses the hand held nitrous oxide deliver device which is intended to be used in nitrous oxide sedation systems by delivering a limited 16 grams of nitrous oxide over a total of 120 seconds of inhalation time. the device creates short term minimal sedation by delivering a maximum 72% usp grade nitrous oxide / 28 % ambient air combination which quickly drops to under 33% nitrous oxide / 67% ambient air in 60 seconds and stays steady until all the gas is expelled.

Eligibility criteria:
inclusion criteria: * any patient undergoing a painful office procedure or exam exclusion criteria: * women that are pregnant * children under three years of age

Keywords: minimal sedation nitrous oxide
a study to evaluate the safety and effect of co-administration of abt-450 with ritonavir (abt-450/r) and abt-267 in adults with chronic hepatitis c virus infection

Conditions: Hepatitis C, Chronic

Summary: the purpose of this study is to evaluate the safety and efficacy of co-administration of abt-450 (also known as paritaprevir) with ritonavir (abt-450/r) and abt-267 (also known as ombitasvir) in adults with chronic hepatitis c virus infection.

this was a phase 2, randomized, open-label, combination treatment study of the 2-daa regimen (abt-450 150 mg qd + ritonavir 100 mg qd + abt-267 25 mg qd) in adult hcv gt1b-infected treatment-naïve and pegylated-interferon/ribavirin (pegifn/rbv) treatment-experienced participants without cirrhosis and with compensated cirrhosis, and in adult gt4-infected treatment-naïve and pegifn/rbv treatment-experienced participants without cirrhosis. treatment group 5 was not open to enrollment, based on a protocol-specified interim review of results from the treatment-naïve gt4 groups 1 and 4 that indicated higher sustained virologic response (svr) rates among participants receiving the 2-daa regimen with rbv. all other groups completed the study.

Eligibility criteria:
inclusion criteria: * females must be practicing specific forms of birth control on study treatment, or be postmenopausal for more than 2 years or surgically sterile * subjects must meet one of the following: * treatment-naive: subject has never received antiviral treatment for hepatitis c infection or * treatment experienced (prior null responders, partial responders or relapsers to pegifn/rbv); * body mass index (bmi) is ≥ 18 to \< 38 kg/m\^2. * chronic hcv genotype 1b infection/with or without cirrhosis or hcv genotype 4 infection/without cirrhosis for at least 6 months prior to study screening. * subject has plasma hcv rna level \> 10,000 iu/ml at screening exclusion criteria: * history of severe, life-threatening or other significant sensitivity to any drug. * females who were pregnant or planned to become pregnant, or breastfeeding, or gt4-infected males whose partners were pregnant or planning to become pregnant within 7 months (or per local rbv label) after their last dose of study drug/rbv. * recent history of drug or alcohol abuse that could preclude adherence to the protocol. * positive test result for hepatitis b surface antigen or anti-human immunodeficiency virus (hiv) antibodies.

Keywords: hepatitis c virus ribavirin-free hepatitis c genotype 1 hepatitis c interferon-free chronic hepatitis c compensated cirrhosis hepatitis c genotype 4 paritaprevir ombitasvir ritonavir ribavirin
exploratory study of ebv dna titre clearance whilst on proton beam therapy

Conditions: Nasopharyngeal Carcinoma; Head and Neck Cancer; Nasopharyngeal Cancer; Epstein-Barr Virus

Summary: how does plasma epstein-barr virus (ebv) dna level change during definitive radiation therapy for nasopharyngeal carcinoma (npc) in the teenage and young adult cohort and does it correlate with outcomes?

children with npc achieve superior survival outcomes compared to adults (10) and the prognostic value of plasma epstein-barr virus (ebv) dna has not been studied in children. integration of mri into early treatment response assessment will add further prognostic value and permits response-adapted therapy which can improve quality of survivorship children through toxicity reduction. it also allows identification of patients who either have had or are likely to have a suboptimal response to treatment, facilitating the potential consideration of treatment escalation. the sample size of this study is not intended to change clinical practice, but rather provide a basis for international collaboration to achieve larger patient numbers.

Eligibility criteria:
inclusion criteria: * children and young adults (8-30 years old) * pathologically confirmed ebv-positive nasopharyngeal carcinoma * stage i-iva (ajcc 8th edition) * planned to commence curative-intent radiation therapy exclusion criteria: * recurrent npc * concurrent or previously treated ebv-associated malignancy * prior radiation therapy * contraindications to mri * general anaesthetic requirement for mri

Keywords: nasopharyngeal, cancer, proton beam, epstein-barr virus